UNI418 Disrupts DNA Repair, Restores PARP Sensitivity
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- UNI418 lowered levels of DNA‑repair proteins RAD51 and CHK1 in cancer cells, impairing homologous recombination.
- Cul4A ubiquitin ligase complex was activated by UNI418, marking DNA‑repair proteins for degradation.
- IP6 signaling was reduced by UNI418, removing its normal restraint on Cul4A activity.
- PARP inhibitor–resistant cancer cells regained sensitivity to the PARP inhibitor Olaparib when treated with UNI418.
- Tumor xenograft models showed slowed tumor growth with the combination of UNI418 and Olaparib, even in resistant cancer models.
- Kyungjae Myung led the research at the Center for Genomic Integrity, Institute for Basic Science, publishing the findings in Nature Communications.
Why it matters: The approach gives oncologists a new tool to overcome PARP‑inhibitor resistance, potentially expanding effective treatment options for patients with refractory cancers, while pharmaceutical developers may gain a target for combination therapies, though UNI418 still needs further development. The findings reveal a metabolic link to genome stability, expanding scientific understanding of DNA repair regulation.
